IONS Stock Price Today (September 2026) — Ionis Pharmaceuticals, Inc. Analysis & Key Metrics 2026-09-03
Ionis Pharmaceuticals, Inc. (IONS) is trading at $58.13, down 5.22% today (as of September 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $89.33 (53.7% upside).
- Volatility remains elevated (34.65% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-40.70% YoY) alongside significant competitive pressures.
IONS Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Ionis Pharmaceuticals, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $10.23B
P/E Ratio
Forward P/E: -55.52
Revenue Growth
Year over Year
Analyst Target
+53.7% upside potential
Key Investor Questions About IONS
What investors need to know before buying
Based on current market data, IONS presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 44.01)
- Fundamentals say: Challenging (declining revenue trends)
IONS's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for IONS investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $2.19B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, IONS stock traded between $49.13 and $86.74—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 34.65% annualized volatility and β=0.61, the stock exhibits low sensitivity to market moves—making IONS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Ionis Pharmaceuticals (IONS) Gains First-Mover Advantage with FDA Approval of Rare Brain Disease Drug
The U.S. FDA has approved Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)’s Zanvastro (zilganersen) as the first FDA-approved treatment for Alexander disease (AxD), a rare, progressive neurological disorder caused by mutations in the GFAP gene. The disease affects fewer than 1,000 people in the U.S. and can lead to seizures, loss of developmental milestones, impaired movement, and other […]
IONS Edges Up After-Hours On FDA’s Green Light For Neurology Drug After Being Dragged Down By Ultragenyx’s Failed Trial
Zanvastro is now approved for children and adults with Alexander disease, a rare and often fatal brain condition that affects fewer than one in a million people.
Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone
This biotech stock looks like a great candidate to buy on the admittedly steep dip.
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?
Indivior Pharmaceuticals Inc. (INDV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Could Ionis Pharmaceuticals (IONS) Stock Become a Biotech Powerhouse as its Commercial Pipeline Takes Off?
On August 20, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced that it will present new cardiometabolic data for TRYNGOLZA (olezarsen) and its investigational siRNA ION775 at the European Society of Cardiology (ESC) Congress 2026 in Munich. Following its June U.S. FDA approval for severe hypertriglyceridemia (sHTG), the spotlight centers on 1-year Phase 3 extension data showing sustained […]
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial — Jefferies Sees Neutral To Negative Readthrough To ALNY
Ionis and AstraZeneca already disclosed on July 9 that the late-stage CARDIO-TTRansform missed its primary goal. Full data from the trial was unveiled on Friday.
Why Is Ionis Pharmaceuticals (IONS) Up 17.2% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam stock drops on rival heart trial: Why analysts see core business safe
Investing.com -- A major clinical trial failure in heart disease is reverberating across Wall Street, wiping hundreds of millions of dollars off the market value of RNA-therapeutics pioneer Alnylam Pharmaceuticals before the opening bell on Friday. Shares of Alnylam (NASDAQ: ALNY) fell nearly 4.9% in pre-market trading following the full presentation of data from a rival drug trial at the European Society of Cardiology Congress in Munich. The detailed results from AstraZeneca and Ionis Pharmaceu
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.
Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales
Ionis Pharmaceuticals stock carries a strong three year return record alongside a high overall value score, yet current market multiples still point to the shares trading at a premium rather than as an obvious bargain. Ionis Pharmaceuticals has delivered a 47.3% return over the past three years, which puts recent pricing in focus for anyone considering new capital at work. The recent securities investigation following the Wainua trial setback may weigh on risk perceptions, while any renewed...
Explore More Analysis for IONS
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. (IONS) is currently trading at $58.13. The RSI (14-day) is at 44.0, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $89.33 implies 53.7% upside from current levels. Volatility is moderate at 34.7% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Ionis Pharmaceuticals, Inc. (IONS): The trailing P/E ratio is -16.70, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is -55.52, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 21.89. Price-to-Sales is 11.05. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 21 analysts covering IONS, the consensus price target is $89.33. This represents a 53.7% upside from the current price of $58.13. The range spans from a low target of $66.00 to a high target of $115.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Ionis Pharmaceuticals, Inc. (IONS) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Ionis Pharmaceuticals, Inc. (IONS) investors include: 1. Moderate volatility (34.7% annualized)—price swings are notable. 2. Elevated debt levels (D/E ratio of 497.80) which could pressure margins in a rising rate environment. 3. Declining revenue (-40.7% YoY), indicating potential business headwinds. 4. Elevated short interest (16.0% of float) suggests significant bearish sentiment. 5. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 6. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Ionis Pharmaceuticals, Inc.'s (IONS) current debt and financial health profile: Total debt stands at $2.19B. The debt-to-equity ratio is 497.80, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 7.89, indicating strong short-term liquidity. The quick ratio is 6.85. The company holds $2.10B in cash and equivalents. Free cash flow is negative at $-346,764,640, which could limit the company's ability to manage debt obligations.